Enterprise Value
304M
Cash
21.9M
Avg Qtr Burn
N/A
Short % of Float
8.18%
Insider Ownership
13.10%
Institutional Own.
89.57%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belrapzo (Bendamustine hydrochloride injection) Details CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma) | Approved Quarterly sales | |
Ryanodex (dantrolene sodium) injectable Details MH (Malignant Hyperthermia) | Approved Quarterly sales | |
Vasopressin Details Vasodilary shock | Approved Quarterly sales | |
Bendeka (Bendamustine hydrochloride) injection Details CLL (Chronic Lymphocytic Leukemia) | Approved Quarterly sales | |
Landiolol Details Supraventricular tachycardia | NDA FDA meeting |